Skip to content

Efficacy of Unani compound formulations and regimen in the management of Obesity

A comparative clinical evaluation of an unani pharmacopoeial formulations and classical regimen in the management of siman-e-mufrit (obesity) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056675
Enrollment
60
Registered
2023-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E668- Other obesity

Interventions

Intervention1: jawarish Falafali and Arq e zeera: jawarish falafali 6gm twice a day and Arq e zeera 12ml twice a day Intervention2: jawarish falafali and arq e zeera riyazat with taqleel e ghiza and s

Sponsors

Department of Ilaj Bit Tadbeer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: BMI more than 30 and less than 39.9 Waist circumference more than 102 cm in men and more than 88 cm in women patient willing to Participate in the study and ready to follow the instructions

Exclusion criteria

Exclusion criteria: Age below 20 years and above 60 years BMI less than 30 and more than 39.9 Waist circumference less than 102 cm in men and less than 88 cm in women Pregnant and lactating Women Patients who fail to give written consent Patient having uncontrolled cardiac, liver and renal disorder unstable and bed ridden patients Patient of portal hypertension and bleeding disorder patient with uncontrolled primary hypertension and diabetes mellitus patients with endocrine disorders that is hypothyroidism, cushing syndrome patients who do not cooperate

Design outcomes

Primary

MeasureTime frame
Body weight decreases BMI decreases Waist circumference decreases waist hip ratio upper arm circumference skin fold thickness lipid profile total cholesterol & triglyceridesTimepoint: Assessment of all parameters at inititation of the study at 0 day 15 day 30 day 45 day & 60 day. Assessment of lipid profile at 0 day & at the end of study 60 day

Secondary

MeasureTime frame
Restricted movement Joints pain Weakness & lethargyTimepoint: assessment of all symptoms at initiation of the study at 0 day 15 day 30 day 45 day & 60 day

Countries

India

Contacts

Public ContactSamreen Farha

Aligarh Muslim University

dr.mskhan@gmail.com9412595931

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026